

Attorney Docket No.: **ISPH-0752**
Serial No.: **10/630,399**
Page 2

This listing of claims will replace all prior versions and listings of claims in the application:

1. (previously presented) A compound 8 to 50 nucleobases in length targeted to the 3' untranslated region of a nucleic acid molecule encoding IL-1 receptor-associated kinase-4, wherein said compound specifically hybridizes with said nucleic acid molecule encoding IL-1 receptor-associated kinase-4 and inhibits the expression of IL-1 receptor-associated kinase-4.
2. (original) The compound of claim 1 which is an antisense oligonucleotide.
3. (canceled).
4. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 8 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Attorney Docket No.: **ISPH-0752**
Serial No.: **10/630,399**
Page 3

9. (original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (original) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding IL-1 receptor-associated kinase-4.

12. (original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (original) The composition of claim 12 further comprising a colloidal dispersion system.

14. (original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. (withdrawn) A method of inhibiting the expression of IL-1 receptor-associated kinase-4 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of IL-1 receptor-associated kinase-4 is inhibited.

Claims 16-20 (canceled).